scholarly journals Application of Fish Collagen-Nanochitosan-Henna Extract Composites for the Control of Skin Pathogens and Accelerating Wound Healing

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Ahmed A. Tayel ◽  
Reem A. Ghanem ◽  
Mohammed S. Al-Saggaf ◽  
Dalia Elebeedy ◽  
Ahmed I. Abd El Maksoud
Keyword(s):  
Local Treatment ◽  
Chitosan Nanoparticles ◽  
Electrophoretic Analysis ◽  
Complete Healing ◽  
Sea Bream ◽  
Type I ◽  
Lawsonia Inermis ◽  
Skin Disinfection ◽  
Fish Collagen ◽  
Ir Spectroscopic

Skin is the largest protective organ that could be recurrently wounded and attacked by microorganisms. The wounded skin safeguarding and supporting were intended through natural derivatives. Fish collagen (Cg) type I, extracted from sea bream (Spondyliosoma cantharus), chitosan nanoparticles (NCht) from shrimp shells, and henna (Lawsonia inermis L.) leaves extract (He) were produced and physiochemically characterized. The antimicrobial potentialities of these compounds and their composites were assessed toward skin pathogens (Candida albicans and Staphylococcus aureus) using various assaying methods and microimaging techniques. The infrared and electrophoretic analysis of Cg validated its characteristics, and the IR-spectroscopic analysis of the compounds/composites indicated their physiochemical attributes and interrelations. The produced NCht particles had a diameter range of 64.6-308.8 nm, 104 nm mean diameter, and +31.3 mV zeta potentiality. Both NCht, He, and NCht/He composite exhibited significant antimicrobial potentiality toward skin pathogens; NCht/He was the strongest with inhibitory concentrations of 20.0 and 22.5 μg/mL and inhibition zones of 25.7 and 26.8 mm against S. aureus and C. albicans, respectively. The electron micrographs verified the synergistic microbicidal action of NCht/He, as they led to severe microbial lysis and deformations. The skin wounds’ treatment with NCht/He/Cg composite promoted the fastest and complete healing of wounded rats’ skin during 8 days of local treatment, with the absence of inflammation and infection signs; treated with NCht/He/Cg composite, the wound area vastly reduced from 63.6 mm2 to 15.9 and 9.1 mm2 after 2 and 4 days, respectively. The natural NCht/He/Cg composites are recommended as topical applications for optimum skin disinfection and regeneration.

scholarly journals Developmental changes in the type I procollagen processing pathway in chick-embryo cornea

1991 ◽  
Vol 276 (3) ◽  
pp. 777-784 ◽  
Author(s):  
S J Mellor ◽  
G L Atkins ◽  
D J S Hulmes
Keyword(s):  
Chick Embryo ◽  
Kinetic Model ◽  
Rate Constants ◽  
Collagen Fibril ◽  
Electrophoretic Analysis ◽  
Developmental Changes ◽  
Type I ◽  
Electron Microscopic ◽  
Type I Procollagen ◽  
Stage Of Development

Type I procollagen processing in chick-embryo corneas was studied at days 12, 14 and 17 of development. Pulse-chase experiments and electrophoretic analysis of salt-soluble extracts showed developmental changes in the processing pathway. A kinetic model was fitted to the data to determine rate constants for processing of both N- and C-propeptides. Data for pro alpha 1(I)-chain processing and pro alpha 2(I)-chain processing were fitted separately (where pro means procollagen). Between days 12 and 17 the relative flux through the pC-collagen (procollagen chain lacking the N-propeptide) and pN-collagen (procollagen chain lacking the C-propeptide) pathways increased approx. 4-fold. Pro alpha 1(I) chains and pro alpha 2(I) chains were processed by slightly different routes. Variations in the rate constants were compared with electron-microscopic measurements of collagen fibril diameters at each stage of development. Diameters increased by less than 10% over the period from 12 to 17 days. It was concluded that fibril diameters are relatively insensitive to the pathway of procollagen processing in the salt-soluble pool.

scholarly journals Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants

Blood ◽  
1995 ◽  
Vol 86 (11) ◽  
pp. 4331-4336 ◽  
Author(s):  
S Chin ◽  
B Williams ◽  
P Gottlieb ◽  
H Margolis-Nunno ◽  
E Ben-Hur ◽  
...  
Keyword(s):  
Factor Viii ◽  
Ultraviolet Light ◽  
Short Wavelength ◽  
Hepatitis A Virus ◽  
Parvovirus B19 ◽  
Electrophoretic Analysis ◽  
Encephalomyocarditis Virus ◽  
Type I ◽  
Virus Elimination ◽  
Plasma Factor

The use of solvent/detergent mixtures and various forms of heat treatment to inactivate viruses has become widespread in the preparation of blood derivatives. Because viruses that lack lipid envelopes and/or are heat resistant, eg, hepatitis A virus (HAV) or parvovirus B19 may be present, the use of two methods of virus elimination that operate by different mechanisms has been advocated. We now report on short wavelength ultraviolet light (UVC) irradiation for virus inactivation and enhancement of its compatibility with proteins by quenchers of reactive oxygen species (ROS). Treatment of an antihemophilic factor (AHF) concentrate or whole plasma with 0.1 J/cm2 inactivated 10(5) to > or = 10(6) infectious doses (ID) of encephalomyocarditis virus (EMCV), HAV, bacteriophage M13, vesicular stomatitis virus (VSV), and porcine parvovirus. However, the recovery of factor VIII was 30% or lower on treatment of an AHF concentrate and 60% on treatment of plasma. Factor VIII recovery could be increased with little or no effect on virus kill by addition of rutin, a flavonoid known to quench both type I and type II ROS. On treatment of plasma in the presence of rutin, the recovery of several other coagulation factors was also enhanced by rutin addition and typically exceeded 75%. Electrophoretic analysis of treated AHF concentrate confirmed the advantage of rutin presence; UVC irradiation of plasma did not cause discernible changes in electrophoretic banding patterns, even in the absence of rutin. We conclude that addition of UVC treatment to existing processes used in the manufacture of blood derivatives will provide an added margin of safety, especially for nonenveloped or heat-stable viruses.

scholarly journals Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051988217
Author(s):  
Dilia Giuggioli ◽  
Federica Lumetti ◽  
Amelia Spinella ◽  
Emanuele Cocchiara ◽  
Gianluca Sighinolfi ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Hypericum Perforatum ◽  
Rating Scale ◽  
Local Treatment ◽  
Skin Lesions ◽  
Complete Healing ◽  
Control Group ◽  
Neem Oil ◽  
Skin Ulcers ◽  
Calcium Deposits

Objective This study evaluated Neem oil and Hypericum perforatum (Holoil®) for treatment of scleroderma skin ulcers related to calcinosis (SU-calc). Procedure: We retrospectively analyzed 21 consecutive systemic sclerosis (SSc) patients with a total of 33 SU-calcs treated daily with Holoil® cream compared with a control group of 20 patients with 26 SU-calcs. Holoil® was directly applied to skin lesions, while the control group received only standard medication. Results Application of Holoil® either resulted in crushing and complete resolution of calcium deposits or facilitated sharp excision of calcinosis during wound care sessions in 27/33 cases (81.8%). Complete healing of SU-calc occurred in 15/33 (45%) of cases within a time period of 40.1 ± 16.3 (mean ± SD) days, while 18/33 (55%) of lesions improved in terms of size, erythema, fibrin and calcium deposits. Patients reported a reduction of pain (mean numeric rating scale 7.3 ± 1.9 at baseline versus 2.9 ± 1.4 at follow-up) The control group had longer healing times and a higher percentage of infections. Conclusions The efficacy of local treatment with neem oil and Hypericum perforatum suggest that Holoil® could be a promising tool in the management of SSc SU-calc.

The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. TPS788-TPS788 ◽  
Author(s):  
Elske C. Gootjes ◽  
Tineke E Buffart ◽  
M.P. Tol ◽  
J Burger ◽  
Dirk J. Grunhagen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Systemic Therapy ◽  
Local Treatment ◽  
Case Series ◽  
Local Therapy ◽  
Phase Iii ◽  
Locoregional Therapy ◽  
Treatment Modalities ◽  
Type I ◽  
Tumor Debulking

TPS788 Background: In the current multidisciplinary approach of mCRC, local treatment of oligometastases is common practice. Results of large case series of selected patients treated with complete surgical resection of metastatic lesions suggest that this approach substantially improves survival rates to around 30-60%. Other techniques such as radiofrequency or microwave ablation (RFA, MWA), transarterial chemoembolization (TACE) or radiotherapy can also be applied in local treatment. Curative treatment options are generally not available for patients with extensive hepatic and/or extrahepatic mCRC. These patients primarily receive palliative systemic treatment consisting of combination chemotherapy as well as targeted agents. So far, reports on the benefit of local treatment for metastases in multi-organ mCRC have major limitations, including being small, non-randomized, single-center and retrospective. The benefit from local treatment of metastases for these patients should be established to allow for interruption of the standard systemic therapy and exposure to possible adverse events from local treatment. Methods: The ‘ORCHESTRA’ trial is a randomized multicenter clinical trial for patients with multi-organ mCRC, comparing the combination of chemotherapy and maximal tumor debulking versuschemotherapy alone (NCT01792934). We will examine the interplay of both efficacy and toxicity for the combination of systemic chemotherapy and locoregional therapy. Our study design incorporates systemic as well as local therapy in the experimental arm and combines local treatment modalities to pursue maximal tumor debulking. We aim to improve overall survival of patients with multi-organ mCRC by maximal tumor debulking after induction chemotherapy with at least six months. A total of 478 patients will be included to meet the primary endpoint (power 80%, type I error rate 5%). We define local treatments feasible when they can be performed within a 3-month time period to prevent extensive delay of systemic therapy. Currently, 60 patients are included in 22 participating Dutch hospitals. Clinical trial information: NCT01792934.

Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6017-6017 ◽  
Author(s):  
William Nassib William ◽  
Lei Feng ◽  
Merrill S. Kies ◽  
Salmaan Ahmed ◽  
George R. Blumenschein ◽  
...  
Keyword(s):  
Primary Endpoint ◽  
Type I Error ◽  
Performance Status ◽  
Local Treatment ◽  
Progression Free Survival ◽  
Type I ◽  
Phase 2 ◽  
First Line ◽  
Double Blind ◽  
Phase 2 Trial

6017 Background: In a single-arm, phase 2 study, we previously demonstrated that in pts with R/M HNSCC, cisplatin, docetaxel and E improved progression-free survival (PFS) compared to historical data (Kim et al., ASCO 2006). Herein, we evaluated this regimen in a single center, randomized, phase 2 trial. Methods: Pts with R/M HNSCC, with a performance status (PS) 0-2, were randomized (1:1) to receive up to 6 cycles of first-line chemotherapy with cisplatin 75 mg/m2 (or carboplatin AUC 6) and docetaxel 75 mg/m2 i.v. on day 1 every 21 days, plus placebo (P) vs. E 150 mg p.o. daily, followed by maintenance P or E until disease progression. The primary endpoint was PFS. With 120 pts, the study had 80% power to detect an improvement in median PFS from 3.0 to 4.9 months with a two-sided type I error rate of 0.1. Results: From 05/2010 to 07/2015, 120 pts were randomized to the P (N = 60) or E (N = 60) groups. All pts but one initiated treatment and were eligible for evaluation of the primary endpoint – 92 males; median age 62 years; 52 oropharynx, 40 oral cavity, 19 larynx, 8 hypopharynx cancer pts; 86 current/former smokers; 43 with recurrence within 6 months of completion of local treatment; 27 with prior exposure to EGFR inhibitors. Median PFS was 4.4 vs. 6.1 months for the P and E groups, respectively (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.42-0.95 months, p = 0.026). Response rates were 44% vs. 56% for P vs. E (p = 0.21). Median overall survival (OS) for P- and E-treated pts was 13.7 vs. 17.0 months (HR = 0.67, 95% CI 0.43-1.04, p = 0.07). Benefits from E on PFS and OS were more pronounced in pts with oropharyngeal tumors (p≤0.05 for interaction). In the E group, first-cycle rash grade 2-4 (34% pts) was associated with longer OS (HR = 0.40, p = 0.02). E-treated pts experienced a higher incidence of grade 3-4 adverse events (33.9 vs. 53.3%), including diarrhea (3 vs.17%), dehydration (5 vs. 15%), nausea (5 vs. 14%), rash (0 vs. 12%). Conclusions: This study met its primary endpoint. Addition of E to first-line platinum/docetaxel improved PFS and OS. This regimen may warrant further evaluation in randomized, phase 3 trials. Clinical trial information: NCT01064479.

scholarly journals Effectiveness of Alkali and Acid to Produce Collagen from Fish Skin of Striped Catifish

2017 ◽  
Vol 20 (2) ◽  
pp. 255
Author(s):  
Hilda Lu’lu’in Nanda Alfira Devi ◽  
Pipih Suptijah ◽  
Mala Nurilmala
Keyword(s):  
Acetic Acid ◽  
Type I Collagen ◽  
Electrophoretic Analysis ◽  
Extraction Process ◽  
Skin Extract ◽  
Type I ◽  
Fish Skin ◽  
Soaking Time ◽  
Randomized Design ◽  
Striped Catfish

Fish skin is one of the alternative sources contained high protein  to isolate collagen. Fish skin generally extracted by the method of acid, alkali and enzymes. The study aim to determine the effectiveness of NaOH<br />and acetic acid on catfish (Pangasius sp.) skin extraction  process.  The concentrations of alkaline pretreatment were 0,05; 0,1; 0,15 and 0,2 M with the soaking time of 2, 4, 6, 8 and 10 h by NaOH replacement in every 2 h. The concentrations of acetic acid for hydrolisis process were 0.05; 0.1; 0.15 and 0.2 M with the soaking time of 1, 2, and 3 h. The experimental design used for pretreatment process is split splot, while for the hydrolysis process is factorial completely randomized design. The results showed that pretreatment with a concentration of 0.05 M NaOH for 4 h has a significant effect for eliminating non-collagen protein (p&lt;0.05). The acetic acid concentration of 0.15 M for 1 h also has a significant effect on fish skin swelling. The yield of striped catfish collagen was 17.272%, the protein content was 86%, and the viscosity was 12 cP. Fish skin extract was identified as type I collagen by functional groups and electrophoretic analysis. Collagen from striped catfish skin has α1 and α2 and protein structure with the molecular weight of α chain were 94 and 98 kDa, meanwhile the molecular wheight of β chain was 204 kD.

Identification of Linear IgE Epitopes for a Major Allergen–Type I Collagen in Fish (Rainbow Trout)

2018 ◽  
Vol 17 (2) ◽  
pp. 206-213
Author(s):  
Wang Yan-Bo ◽  
Li Xiao-Hui ◽  
Zhou Jin-Ru ◽  
Zhang Yan ◽  
Ma Ai-Jin ◽  
...  
Keyword(s):  
Rainbow Trout ◽  
Type I Collagen ◽  
Solid Phase ◽  
Strong Support ◽  
Major Allergen ◽  
Cross Reactivity ◽  
Type I ◽  
Linear Epitope ◽  
Fish Collagen ◽  
P Type

Type I collagen was described as a major allergen in fish. The purpose of this study was to screen and identify the linear IgE epitopes of type I collagen α1 and α2 subunits in rainbow trout. Five bioinformatics tools were used to predict the potential epitopes and the resultant epitopes were confirmed by LAD2 cells degranulation assay with sera from fish allergic patients. As the result, 10 peptides of α1 and α2 subunits were predicted, respectively, and these peptides were assembled by solid-phase synthesis. 14 epitopes were identified by LAD2 cells degranulation assay, among which, peptide 2, 5–7 were identified as linear epitope of α1 and peptide 11–20 were identified as linear epitope of α2. Moreover, for α1 and α2 subunits, the similarity of sequences was greater than 79%, suggesting the cross-reactivity of fish collagen. The findings of this study provided a strong support for further research of reduction of the collagen allergenicity.

A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5130-5130
Author(s):  
V. J. Sinibaldi ◽  
M. A. Carducci ◽  
S. Moore-Cooper ◽  
B. George ◽  
S. Denmeade ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Type I Error ◽  
Local Treatment ◽  
Hepatic Function ◽  
Dose Effect ◽  
Progression Rate ◽  
Type I ◽  
Antitumor Effects ◽  
Double Blind ◽  
Pooled Data

5130 Background: BR following LT is common in PC with no defined standard treatment. Lenalidomide (L) is an immunomodulatory agent with anti-angiogenic and direct antitumor effects. Methods: This trial was designed to evaluate a dose-effect relationship of L in BR PC. Pts were randomized to either 5 or 25 mg/day(d), PO, d 1–21 (28-d cycles); then stratified by PSADT (< 3, 3–8.9, ≥ 9 mos), LT and prior ADT. Eligible pts had: rising PSA (≥1 ng/mL), M0 disease, testosterone > 150 ng/mL, adequate bone marrow, renal, and hepatic function. Baseline and Q 2 mos PSA's were processed after Q 6 mos of L, along with CT and bone scan. Toxicity exams were Q mo. Primary endpoints are safety and progression after 6 mo of L (defined by a confirmed ↑ in PSA > 25% over the baseline value or mets). Secondary endpoints are changes of slopes in PSA related to pharmacokinetics (pk). A sample size of 30 pts/arm provides an 85% power to detect a PSA progression rate of 40% (compared to 80% predicted ) with a Type I error = 0.05 (Fishers exact test). Results: 59 pts were entered July 20, 2006-December 31, 2008. Pooled data from the 2 arms: median: age 64 (50–81), ECOG PS 0, baseline PSA 9.3 ng/ml (1.3–92.8 ng/ml). 16 pts had PSADT <3 mos, 26 from 3–8.9 mos, and 17 ≥ 9 mos. Median: F/U on all 59 pts is 351 + d (9 +-887+d); # cycles = 6 (1–30). Thus far, 44/59 pts completed 6 cycles of L (1 had PD, 6 stopped L due to toxicity, 8 too early). 22 /44 who completed 6 mos of L remained on L > 6 mos ( 7+-30+ mos); including 7 pts ≥ 24 mos. Of 44 pts, blinded evaluation of PSA's at 6 mos: 4 pts had ≥ 50% ↓, 22 had stable PSA,17 had PD, 1 too early . Rash was DLT. Other Gr toxicities: appendicitis, abd pain, neck pain, venous thrombolic disease, fatigue, pruritus. Conclusions: Preliminary data prior to unblinding the study treatment arms, from pooled data, suggest that L may be administered > 6 mos with acceptable toxicity, and is associated with PSA declines and long term stabilization in pts with BR. Supported by a grant from Celgene Corporation. Data coordination infrastructure is supported by the Prostate Cancer Foundation and The James Stine research fund. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document